LiverMultiScan诊断MASLD的效用和成本效益:一项真实世界的多国随机临床试验。

IF 5.4 Q1 MEDICINE, RESEARCH & EXPERIMENTAL Communications medicine Pub Date : 2025-03-18 DOI:10.1038/s43856-025-00796-9
Elizabeth Shumbayawonda, Marika French, Jane Elizabeth Carolan, Cayden Beyer, Paula Lorgelly, Dimitar Tonev, Rajarshi Banerjee, Michael H Miller, Christopher D Byrne, Janisha Patel, Saima Ajaz, Kosh Agarwal, Johanna Backhus, Minneke J Coenraad, Jelte J Schaapman, Andrew Fraser, Miguel Castelo Branco, Stephen Barclay, Matthias M Dollinger, Daniel J Cuthbertson, Daniel Forton, Hildo J Lamb
{"title":"LiverMultiScan诊断MASLD的效用和成本效益:一项真实世界的多国随机临床试验。","authors":"Elizabeth Shumbayawonda, Marika French, Jane Elizabeth Carolan, Cayden Beyer, Paula Lorgelly, Dimitar Tonev, Rajarshi Banerjee, Michael H Miller, Christopher D Byrne, Janisha Patel, Saima Ajaz, Kosh Agarwal, Johanna Backhus, Minneke J Coenraad, Jelte J Schaapman, Andrew Fraser, Miguel Castelo Branco, Stephen Barclay, Matthias M Dollinger, Daniel J Cuthbertson, Daniel Forton, Hildo J Lamb","doi":"10.1038/s43856-025-00796-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Increasing prevalence of metabolic dysfunction-associated liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) poses a growing healthcare burden. Noninvasive diagnostic tools to replace liver biopsy are urgently needed. We investigated the utility and cost-effectiveness of including multiparametric magnetic resonance imaging (mpMRI) to the management of adults with suspected MASLD multi-nationally.</p><p><strong>Methods: </strong>RADIcAL-1, a 1:1 randomised controlled trial (standard-of-care [SoC] vs. imaging arm [IA; SoC+mpMRI]) included 802 participants from Germany, Netherlands, Portugal and UK. Wilcoxon-rank tests were used to compare access to healthcare practitioners, patient assessments and proportion of patients with a diagnosis (%diagnosis). Liver fat and disease activity (corrected T1 [cT1]) were used to identify patients not requiring biopsy in the imaging arm. Primary endpoint was mpMRI cost-effectiveness and improvement in resource use (visits avoided) using mpMRI.</p><p><strong>Results: </strong>mpMRI is cost-effective with an ICER of €4968/QALY gained. 403 were randomised to IA and 399 to SoC. SoC has significantly more specialist appointments (p = 0.015) and patient assessments (p < 0.001). Across all involved hospitals, %diagnosis is significantly higher in the imaging arm (p = 0.0012). cT1 correctly classifies 50% of patients without MASH with fibrosis and can avoid biopsy. Including all costs, the imaging arm incurs higher short-term per-patient healthcare expenditure compared to the SoC arm (€1,300 vs. €830).</p><p><strong>Conclusion: </strong>Adding mpMRI to SoC for the management of adults with suspected MASLD multi-nationally is cost-effective, enhances rate of diagnosis multi-nationally and increases rate of diagnosis without increasing other liver-related health care resource use. Due to the need for standardisation of SoC, widespread use can support optimisation of the MASLD clinical pathway and improve long-term patient management.</p>","PeriodicalId":72646,"journal":{"name":"Communications medicine","volume":"5 1","pages":"74"},"PeriodicalIF":5.4000,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11920111/pdf/","citationCount":"0","resultStr":"{\"title\":\"Utility and cost-effectiveness of LiverMultiScan for MASLD diagnosis: a real-world multi-national randomised clinical trial.\",\"authors\":\"Elizabeth Shumbayawonda, Marika French, Jane Elizabeth Carolan, Cayden Beyer, Paula Lorgelly, Dimitar Tonev, Rajarshi Banerjee, Michael H Miller, Christopher D Byrne, Janisha Patel, Saima Ajaz, Kosh Agarwal, Johanna Backhus, Minneke J Coenraad, Jelte J Schaapman, Andrew Fraser, Miguel Castelo Branco, Stephen Barclay, Matthias M Dollinger, Daniel J Cuthbertson, Daniel Forton, Hildo J Lamb\",\"doi\":\"10.1038/s43856-025-00796-9\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Increasing prevalence of metabolic dysfunction-associated liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) poses a growing healthcare burden. Noninvasive diagnostic tools to replace liver biopsy are urgently needed. We investigated the utility and cost-effectiveness of including multiparametric magnetic resonance imaging (mpMRI) to the management of adults with suspected MASLD multi-nationally.</p><p><strong>Methods: </strong>RADIcAL-1, a 1:1 randomised controlled trial (standard-of-care [SoC] vs. imaging arm [IA; SoC+mpMRI]) included 802 participants from Germany, Netherlands, Portugal and UK. Wilcoxon-rank tests were used to compare access to healthcare practitioners, patient assessments and proportion of patients with a diagnosis (%diagnosis). Liver fat and disease activity (corrected T1 [cT1]) were used to identify patients not requiring biopsy in the imaging arm. Primary endpoint was mpMRI cost-effectiveness and improvement in resource use (visits avoided) using mpMRI.</p><p><strong>Results: </strong>mpMRI is cost-effective with an ICER of €4968/QALY gained. 403 were randomised to IA and 399 to SoC. SoC has significantly more specialist appointments (p = 0.015) and patient assessments (p < 0.001). Across all involved hospitals, %diagnosis is significantly higher in the imaging arm (p = 0.0012). cT1 correctly classifies 50% of patients without MASH with fibrosis and can avoid biopsy. Including all costs, the imaging arm incurs higher short-term per-patient healthcare expenditure compared to the SoC arm (€1,300 vs. €830).</p><p><strong>Conclusion: </strong>Adding mpMRI to SoC for the management of adults with suspected MASLD multi-nationally is cost-effective, enhances rate of diagnosis multi-nationally and increases rate of diagnosis without increasing other liver-related health care resource use. Due to the need for standardisation of SoC, widespread use can support optimisation of the MASLD clinical pathway and improve long-term patient management.</p>\",\"PeriodicalId\":72646,\"journal\":{\"name\":\"Communications medicine\",\"volume\":\"5 1\",\"pages\":\"74\"},\"PeriodicalIF\":5.4000,\"publicationDate\":\"2025-03-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11920111/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Communications medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1038/s43856-025-00796-9\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Communications medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1038/s43856-025-00796-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

背景:代谢性功能障碍相关肝病(MASLD)和代谢性功能障碍相关脂肪性肝炎(MASH)的患病率日益增加,造成了越来越大的医疗负担。迫切需要无创诊断工具来替代肝活检。我们调查了包括多参数磁共振成像(mpMRI)在内的多参数磁共振成像(mpMRI)在多国疑似MASLD成人治疗中的效用和成本效益。方法:RADIcAL-1,一项1:1随机对照试验(标准治疗组[SoC]与成像组[IA];SoC+mpMRI])包括来自德国、荷兰、葡萄牙和英国的802名参与者。使用wilcoxon秩检验来比较获得医疗保健从业人员、患者评估和诊断的患者比例(诊断百分比)。肝脏脂肪和疾病活动度(校正T1 [cT1])用于识别成像组不需要活检的患者。主要终点是使用mpMRI的成本效益和资源利用的改善(避免就诊)。结果:mpMRI具有成本效益,ICER为4968欧元/QALY。403例随机分到IA组,399例随机分到SoC组。结论:在SoC中加入mpMRI对多国疑似MASLD成人的管理具有成本效益,提高了多国诊断率,并且在不增加其他肝脏相关卫生保健资源使用的情况下提高了诊断率。由于SoC标准化的需要,广泛使用可以支持优化MASLD临床途径并改善长期患者管理。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

摘要图片

摘要图片

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Utility and cost-effectiveness of LiverMultiScan for MASLD diagnosis: a real-world multi-national randomised clinical trial.

Background: Increasing prevalence of metabolic dysfunction-associated liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) poses a growing healthcare burden. Noninvasive diagnostic tools to replace liver biopsy are urgently needed. We investigated the utility and cost-effectiveness of including multiparametric magnetic resonance imaging (mpMRI) to the management of adults with suspected MASLD multi-nationally.

Methods: RADIcAL-1, a 1:1 randomised controlled trial (standard-of-care [SoC] vs. imaging arm [IA; SoC+mpMRI]) included 802 participants from Germany, Netherlands, Portugal and UK. Wilcoxon-rank tests were used to compare access to healthcare practitioners, patient assessments and proportion of patients with a diagnosis (%diagnosis). Liver fat and disease activity (corrected T1 [cT1]) were used to identify patients not requiring biopsy in the imaging arm. Primary endpoint was mpMRI cost-effectiveness and improvement in resource use (visits avoided) using mpMRI.

Results: mpMRI is cost-effective with an ICER of €4968/QALY gained. 403 were randomised to IA and 399 to SoC. SoC has significantly more specialist appointments (p = 0.015) and patient assessments (p < 0.001). Across all involved hospitals, %diagnosis is significantly higher in the imaging arm (p = 0.0012). cT1 correctly classifies 50% of patients without MASH with fibrosis and can avoid biopsy. Including all costs, the imaging arm incurs higher short-term per-patient healthcare expenditure compared to the SoC arm (€1,300 vs. €830).

Conclusion: Adding mpMRI to SoC for the management of adults with suspected MASLD multi-nationally is cost-effective, enhances rate of diagnosis multi-nationally and increases rate of diagnosis without increasing other liver-related health care resource use. Due to the need for standardisation of SoC, widespread use can support optimisation of the MASLD clinical pathway and improve long-term patient management.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Polygenic risk score with KLK3 SNP-SNP interaction pairs for predicting prostate cancer aggressiveness. Applying a causal biopsychosocial model to guide medicine and psychiatry fifty years after Engel. Advancing radiology foundation models with reasoning through step-by-step verification from daily reports. Microplastics as both a driver of genitourinary cancers and a deliverer of treatments. Estimating investment costs to improve hypertension care in Lagos, Nigeria.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1